Product Update
Is REMplenish Still in Business? (2026 Update)
Is REMplenish from Shark Tank still around in 2026? The deal it made, the sharks who invested, and where to buy REMplenish today.
As an Amazon Associate I earn from qualifying purchases.
REMplenish is a rare case on this site: the on-air deal fell apart after the episode aired, and the company kept growing anyway. Founder Anders Olmanson brought his Myo-Nozzle straw, a device built to train tongue and throat muscles to reduce snoring, out of the Twin Cities area and into a Season 17 episode that aired March 18, 2026. What happened after is worth spelling out clearly.
The Short Answer
Yes, REMplenish is still in business, and it is doing well despite the deal not closing. The company sells primarily direct to consumer through its own website, offering the Myo-Nozzle in multiple bottle configurations, including plastic and stainless steel versions with different resistance levels.
It is not currently listed as selling through Amazon, so the official site is the place to buy it.
The Shark Tank Pitch
Olmanson pitched REMplenish in Season 17, Episode 14, presenting the Myo-Nozzle as a myofunctional therapy tool, essentially a specialized straw that strengthens the muscles involved in snoring and airway function through regular use.
He asked for 400,000 dollars in exchange for 4 percent equity, a confident valuation for a wellness device still building out its retail footprint.
The Deal That Got Done
On air, Kevin O'Leary and Daniel Lubetzky agreed to invest 400,000 dollars for 10 percent equity, a deal that looked like a strong outcome for Olmanson going into the episode's closing minutes.
That deal never actually closed. After further due diligence and negotiation off camera, the investment fell through, which happens more often with Shark Tank deals than the show's ending typically suggests. Olmanson kept building the company without the shark money.
Why the Deal Falling Through Did Not Sink It
A collapsed Shark Tank deal usually gets treated as bad news, but for REMplenish it seems to have barely registered as a setback. Olmanson had already built the Myo-Nozzle around real demand for snoring solutions, a category that affects a huge share of adults and has very few well-designed consumer products addressing it directly. That existing market pull gave the company a path forward even without O'Leary and Lubetzky's capital.
Sponsoring an international myofunctional therapy conference like Tongue Time is not the move of a struggling company trying to manufacture buzz. It is the kind of investment a business makes when it has the revenue to spend on credibility inside a specialized clinical community, which tends to pay off in referrals and long-term brand trust rather than a quick spike in sales.
REMplenish net worth in 2026
REMplenish has not published an official net worth or valuation figure. What is publicly reported is revenue: the company reported roughly 7 million dollars in revenue in 2025, a strong number for a company that closed its television season without the investment it appeared to have secured.
That revenue figure is not the same thing as a company valuation, and no independently audited net worth has been disclosed. Treat any specific dollar valuation attached to REMplenish as an outside estimate rather than a confirmed figure.
Where Things Stand Now
Recap: REMplenish pitched in Season 17, Episode 14, asked for 400,000 dollars at 4 percent equity, and had an on-air agreement with Kevin O'Leary and Daniel Lubetzky for 400,000 dollars at 10 percent that fell apart during post-show due diligence.
The company kept moving regardless. It reported around 7 million dollars in revenue for 2025 and has pushed into international markets, serving as a Platinum Sponsor at Tongue Time 2026, a myofunctional therapy conference held in St. Gallen, Switzerland, a sign the brand is building credibility within the clinical and therapy community, not just chasing direct-to-consumer sales.
If you came here wondering whether the fallen-through deal sank REMplenish, it did not. The company is still selling, still growing, and still building a name for itself even without the shark on its cap table. That is a useful reminder for anyone tracking Shark Tank companies: a deal that never closes is not automatically a death sentence, and REMplenish's roughly 7 million dollars in 2025 revenue is proof that a strong product with real demand behind it can outgrow the loss of a shark's money and connections.
Where to buy REMplenish
Still selling as of May 16, 2026. Check today's price and availability.
Affiliate link — we may earn a commission at no extra cost to you.
See the full REMplenish deal breakdown and term sheet →
